Breaking Bottlenecks in Life Sciences R&D with AI Innovation - with Aziz Nazha of Incyte Pharmaceuticals

Life sciences organizations face significant friction when translating advanced AI capabilities into measurable business outcomes, primarily due to cultural resistance, talent shortages, fragmented data infrastructure, and unrealistic performance expectations. Aziz Nazha, Global Head of AI Innovations Institute at Incyte Pharmaceuticals, emphasizes that successful AI integration requires shifting from a focus on technology to a rigorous redesign of existing scientific workflows. Rather than viewing AI as a plug-and-play solution, leaders must prioritize upskilling the workforce through job-specific training and provide clear guidance on the use of AI tools to mitigate risks associated with shadow AI. By treating AI as a catalyst for process optimization—such as accelerating molecule identification from months to days—organizations can achieve incremental, sustainable gains in drug discovery success rates rather than chasing unattainable, immediate transformations.